1
|
Wang Y, Kim M, Buckley C, Maynard HD, Langley RJ, Perry JK. Growth hormone receptor agonists and antagonists: From protein expression and purification to long-acting formulations. Protein Sci 2023; 32:e4727. [PMID: 37428391 PMCID: PMC10443362 DOI: 10.1002/pro.4727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Revised: 07/06/2023] [Accepted: 07/07/2023] [Indexed: 07/11/2023]
Abstract
Recombinant human growth hormone (rhGH) and GH receptor antagonists (GHAs) are used clinically to treat a range of disorders associated with GH deficiency or hypersecretion, respectively. However, these biotherapeutics can be difficult and expensive to manufacture with multiple challenges from recombinant protein generation through to the development of long-acting formulations required to improve the circulating half-life of the drug. In this review, we summarize methodologies and approaches used for making and purifying recombinant GH and GHA proteins, and strategies to improve pharmacokinetic and pharmacodynamic properties, including PEGylation and fusion proteins. Therapeutics that are in clinical use or are currently under development are also discussed.
Collapse
Affiliation(s)
- Yue Wang
- Liggins Institute, University of AucklandAucklandNew Zealand
- Maurice Wilkins Centre for Molecular BiodiscoveryAucklandNew Zealand
| | - Minah Kim
- Liggins Institute, University of AucklandAucklandNew Zealand
| | - Chantal Buckley
- Liggins Institute, University of AucklandAucklandNew Zealand
| | - Heather D. Maynard
- Department of Chemistry and Biochemistry and the California NanoSystems InstituteUniversity of CaliforniaLos AngelesCaliforniaUSA
| | - Ries J. Langley
- Maurice Wilkins Centre for Molecular BiodiscoveryAucklandNew Zealand
- Department of Molecular Medicine and PathologyUniversity of AucklandAucklandNew Zealand
| | - Jo K. Perry
- Liggins Institute, University of AucklandAucklandNew Zealand
- Maurice Wilkins Centre for Molecular BiodiscoveryAucklandNew Zealand
| |
Collapse
|
2
|
Wang XD, Yu WJ, Liu JH, Du J, Chen KN, Hu QQ, Sun WL, Ying GQ. Preparation and Characterization of Site-Specific Fatty Chain-Modified Recombinant Human Granulocyte Colony Stimulating Factor. Front Bioeng Biotechnol 2022; 10:923059. [PMID: 35677307 PMCID: PMC9168434 DOI: 10.3389/fbioe.2022.923059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2022] [Accepted: 05/05/2022] [Indexed: 11/13/2022] Open
Abstract
The clinical use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) is limited by its short serum half-life. In this study, a long-acting strategy for site-specific modification of rhG-CSF with 1-pentadecyl-1H-pyrrole-2,5-dione (C15 fatty chain-maleimide, C15-MAL) was studied in mixed DMSO-aqueous solutions. The factors influencing the conjugation reaction were investigated and optimized, and a high yield of the desired product (C15-rhG-CSF) was achieved. Subsequently, C15-rhG-CSF product was efficiently purified using preparative liquid chromatography, and further characterized. Circular dichroism spectroscopy analysis showed that the secondary structure of C15-rhG-CSF had no significant difference from unmodified rhG-CSF. C15-rhG-CSF retained 87.2% of in vitro bioactivity of unmodified rhG-CSF. The pharmacokinetic study showed that the serum half-life of C15-rhG-CSF in mice was 2.08-fold longer than that of unmodified rhG-CSF. Furthermore, C15-rhG-CSF by single-dose subcutaneous administration showed better in vivo efficacy than those of both PEG10k-rhG-CSF by single-dose administration and rhG-CSF by multiple doses administration. This study demonstrated the potential of C15-rhG-CSF being developed into a novel drug candidate as well as an efficient process for the development of long-acting protein and peptide drugs.
Collapse
Affiliation(s)
- Xu-Dong Wang
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China
- *Correspondence: Xu-Dong Wang, ; Wen-Long Sun, ; Guo-Qing Ying,
| | - Wei-Jia Yu
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China
| | - Jia-Hui Liu
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China
| | - Jie Du
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China
| | - Kang-Nan Chen
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China
| | - Qin-Qin Hu
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China
| | - Wen-Long Sun
- Institute of Biomedical Research, School of Life Sciences, Shandong University of Technology, Zibo, China
- *Correspondence: Xu-Dong Wang, ; Wen-Long Sun, ; Guo-Qing Ying,
| | - Guo-Qing Ying
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China
- *Correspondence: Xu-Dong Wang, ; Wen-Long Sun, ; Guo-Qing Ying,
| |
Collapse
|
3
|
Wang H, Duan B, Li H, Li S, Lu Y, Liu Z, Su W. PEGylation and macroporous carrier adsorption enabled long-term enzymatic transesterification. NEW J CHEM 2020. [DOI: 10.1039/c9nj05265h] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A novel enzyme catalyst with excellent stability and catalytic efficiency expected to be used in the ERD industry was prepared.
Collapse
Affiliation(s)
- Honghai Wang
- School of Chemical Engineering
- Hebei University of Technology
- Tianjin 300130
- China
- National-Local Joint Engineering Laboratory for Energy Conservation of Chemical Process Integration and Resources Utilization
| | - Baoxuan Duan
- School of Chemical Engineering
- Hebei University of Technology
- Tianjin 300130
- China
- National-Local Joint Engineering Laboratory for Energy Conservation of Chemical Process Integration and Resources Utilization
| | - Hao Li
- School of Chemical Engineering
- Hebei University of Technology
- Tianjin 300130
- China
- National-Local Joint Engineering Laboratory for Energy Conservation of Chemical Process Integration and Resources Utilization
| | - Shihao Li
- Department of Biochemical Engineering and Key Laboratory of Systems Bioengineering of the Ministry of Education
- School of Chemical Engineering and Technology
- Tianjin University
- Tianjin 300072
- China
| | - Yifan Lu
- School of Chemical Engineering
- Hebei University of Technology
- Tianjin 300130
- China
- National-Local Joint Engineering Laboratory for Energy Conservation of Chemical Process Integration and Resources Utilization
| | - Zhiling Liu
- School of Chemical Engineering
- Hebei University of Technology
- Tianjin 300130
- China
- National-Local Joint Engineering Laboratory for Energy Conservation of Chemical Process Integration and Resources Utilization
| | - Weiyi Su
- School of Chemical Engineering
- Hebei University of Technology
- Tianjin 300130
- China
- National-Local Joint Engineering Laboratory for Energy Conservation of Chemical Process Integration and Resources Utilization
| |
Collapse
|
4
|
Zheng H, Yu WL, Guo X, Zhao YZ, Cui Y, Hu T, Zhong JY. An effective immobilized haloalkane dehalogenase DhaA from Rhodococcus rhodochrous by adsorption, crosslink and PEGylation on meso-cellular foam. Int J Biol Macromol 2018; 125:1016-1023. [PMID: 30576728 DOI: 10.1016/j.ijbiomac.2018.12.127] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2018] [Revised: 12/01/2018] [Accepted: 12/16/2018] [Indexed: 12/30/2022]
Abstract
Haloalkane dehalogenase DhaA catalyzes the hydrolysis of halogenated compounds by cleavage of the carbon-halogen bond. However, DhaA suffers from poor environmental stability and difficult recovery, which significantly increase the cost of DhaA. Here, an effective enzyme immobilization strategy was developed to overcome the disadvantages of DhaA. DhaA was physically absorbed with amine-functionalized meso-cellular foam (MCF). The MCF-absorbed DhaA (MD) was intermolecularly crosslinked with 8-arm PEG N‑hydroxysuccinimide ester and then PEGylated by maleimide-thiol chemistry. DhaA from Rhodococcus rhodochrous was absorbed at a loading capacity of 100 mg/g in MD. The bulk crystallinity and morphology of MCF were largely maintained. The immobilized DhaA (MD-P1-P2) showed a lower Michaelis constant (Km, 0.588 mM) than DhaA (0.905 mM), along with an extremely low leaching ratio of DhaA (1.1%) from MCF. MD-P1-P2 exhibited a high stability in the extreme environmental conditions, as reflected by the remaining activity of 99.8% in 40% (v/v) DMSO for 5 h, 87.3% in 3 M urea solution for 1 h, 25.9% at pH 3.0, and 51.8% at room temperature for 30 days. Thus, our study was expected to develop an effective immobilized DhaA for practical application.
Collapse
Affiliation(s)
- He Zheng
- State Key Laboratory of NBC Protection for Civilian, Research Institute of Chemical Defense, Beijing 102205, China
| | - Wei-Li Yu
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China
| | - Xuan Guo
- State Key Laboratory of NBC Protection for Civilian, Research Institute of Chemical Defense, Beijing 102205, China
| | - Yuan-Zhong Zhao
- State Key Laboratory of NBC Protection for Civilian, Research Institute of Chemical Defense, Beijing 102205, China
| | - Yan Cui
- State Key Laboratory of NBC Protection for Civilian, Research Institute of Chemical Defense, Beijing 102205, China
| | - Tao Hu
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China.
| | - Jin-Yi Zhong
- State Key Laboratory of NBC Protection for Civilian, Research Institute of Chemical Defense, Beijing 102205, China.
| |
Collapse
|
5
|
Chang X, Yu W, Ji S, Shen L, Tan A, Hu T. Conjugation of PEG-hexadecane markedly increases the immunogenicity of pneumococcal polysaccharide conjugate vaccine. Vaccine 2017; 35:1698-1704. [DOI: 10.1016/j.vaccine.2017.02.027] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2016] [Revised: 02/13/2017] [Accepted: 02/14/2017] [Indexed: 11/17/2022]
|
6
|
Zhou L, Wang HY, Tong S, Okamoto CT, Shen WC, Zaro JL. Single chain Fc-dimer-human growth hormone fusion protein for improved drug delivery. Biomaterials 2017; 117:24-31. [DOI: 10.1016/j.biomaterials.2016.11.051] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2016] [Revised: 11/25/2016] [Accepted: 11/26/2016] [Indexed: 01/09/2023]
|